Substance-Related Disorders: Clinical Trials

7,454 trials for Substance-Related Disorders, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

4774 completed, 805 recruiting, 657 unknown, 347 terminated. 3467 Not applicable, 1461 Phase 2, 778 Phase 1, 536 Phase 3, 461 Phase 4.

By phase and status

PhaseTrialsStatus
Not applicable3467Completed 2124, Recruiting 460, Unknown 314, Not yet recruiting 168, Active not recruiting 148, Terminated 113, Withdrawn 86, Enrolling by invitation 41, Suspended 13
Phase 21461Completed 1002, Recruiting 127, Terminated 90, Unknown 85, Withdrawn 76, Not yet recruiting 44, Active not recruiting 29, Suspended 5, Enrolling by invitation 3
Phase 1778Completed 544, Recruiting 60, Unknown 58, Terminated 41, Withdrawn 35, Active not recruiting 22, Not yet recruiting 17, Enrolling by invitation 1
Phase 3536Completed 366, Unknown 51, Recruiting 38, Terminated 38, Withdrawn 20, Not yet recruiting 10, Active not recruiting 9, Enrolling by invitation 2, Suspended 2
Phase 4461Completed 308, Terminated 41, Unknown 35, Recruiting 31, Withdrawn 26, Not yet recruiting 11, Active not recruiting 5, Enrolling by invitation 2, Suspended 2
Early Phase 1156Completed 91, Recruiting 19, Terminated 13, Not yet recruiting 12, Unknown 10, Active not recruiting 6, Withdrawn 5

Follow Substance-Related Disorders: new trials by email Literature Review of Substance-Related Disorders trials Research Report on Substance-Related Disorders

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Effects of Cannabidiol on Psychiatric Symptoms, Cognition, and Cannabis Consumption in Cannabis Users With Recent-Onset Psychosis
Cannabidiol (CBD), Placebo - Schizophrenia Spectrum Disorders, Cannabis Use
Phase 2WithdrawnUniversity of Maryland, Baltimore2050-01-012021-04-19
A Hybrid Type 1 Randomized Controlled Trial of an Online and Text-Messaging Intervention to Prevent Alcohol and Cannabis Initiation, Escalation, and Consequences Among First-Year College Students
Online and Text Message Intervention - Alcohol, Cannabis
Not applicableNot yet recruitingThe University of Texas at Arlington8002028-09-012026-10-30
RISE for PTSD and Substance Use Disorder in Veterans
Written Exposure Therapy, Cognitive Behavioral Therapy for Substance Use Disorders (skill components), Cognitive Behavioral Therapy for Substance Use Disorders - Stress Disorders, Post-Traumatic, Substance-Related Disorders
Not applicableNot yet recruitingVA Office of Research and Development302028-08-012026-10-29
The Development of a Transdiagnostic Intervention to Improve Social Functioning and Intimate Relationships Among Veterans
Acceptance and Commitment Therapy for Social Health, Achievement, and Relationship Effectiveness (ACT-SHARE) - Alcohol Problems, Post-Traumatic Stress Disorder
Not applicableNot yet recruitingVA Office of Research and Development292028-07-032026-11-02
Dynamic Treatment Regimes for Opioid Use Disorder
Medication for opioid use disorder, psychotherapy - Opioid Use Disorder
Phase 2Not yet recruitingBrigham and Women's Hospital752028-07-012025-11-04
Integrated Care Versus Usual Care for Opioid Use Disorder and Infectious Diseases in Veterans
Integrated care - Opioid Use Disorder, HIV
Not applicableNot yet recruitingVA Office of Research and Development602028-04-032026-04-24
A Digital Pill System to Measure and Support Acamprosate Adherence in Individuals With Alcohol Associated Liver Disease
AcamproSync - Alcohol Use Disorder, Alcohol Associated Liver Disease
Not applicableNot yet recruitingYale University502027-10-012026-04-28
Smoking Cessation Medication And Rewards Using a Teamlet to Treat Tobacco Use Disorder (SMARTTT 2.0) Among Persons With HIV: A Multi-site Hybrid Type 2 Effectiveness-implementation Trial
nicotine patch, nicotine gum, nicotine lozenge, varenicline, bupropion, Multi-target Contingency Management, Teamlet booster - Tobacco Use Disorder/Cigarette Smoking, HIV
Phase 4Not yet recruitingYale University7942027-09-302026-09-23
Self-administered Neurostimulation Intervention for Firefighter Traumatic Stress to Reduce Alcohol Use: Pilot Study
Transcutaneous auricular neurostimulation (tAN), Active Sham - Posttraumatic Stress Symptoms, Heavy Alcoholic Consumption
Not applicableNot yet recruitingUniversity of Cincinnati202027-09-012026-10-09
Family-Focused Study to Support Medication for Opioid Use Disorder
FamilyCHESS, Standard of Care - Opioid Use Disorder, Opioid Use Disorder, Moderate
Not applicableNot yet recruitingUniversity of Wisconsin, Madison3382027-08-312026-07-07
Adapting a Telehealth Intervention for Suicide Prevention Among Patients With Alcohol Use Disorder in Tanzania
IDEAS-AUD - Alcohol Use Disorder, Suicide Prevention
Not applicableNot yet recruitingDuke University302027-08-012026-03-17
MedSMA℞T Mobile ED
MedSMA℞T Mobile - Opiate-Related Disorders, Opiate Use Disorder
Not applicableNot yet recruitingOlufunmilola Abraham2442027-08-012026-10-09
Medically Supervised Ibogaine With 12-Month Digital Recovery Support for Opioid Use Disorder
Ibogaine Hydrochloride, Extended-release naltrexone injection, 380 mg, Matching Oral Placebo - Opioid Use Disorder, Opioid Withdrawal
Phase 1 / Phase 2Not yet recruitingClive Michelsen602027-07-012026-10-13
Permanent Supportive Housing Overdose Prevention+ Study
TA Intervention - Overdose, Substance Use
Not applicableNot yet recruitingNYU Langone Health29402027-07-012026-05-06
Efficacy and Safety of NTI164 in Children and Young Adults With Rett Syndrome
NTI164, Placebo - RETT Syndrome With Proven MECP2 Mutation, Rett Syndrome
Phase 2 / Phase 3Not yet recruitingFenix Innovation Group402027-07-012026-09-09
Development of a Mobile Health Intervention to Support Functioning of Veterans With Substance Use Disorders
METS4Vets - Substance Use
Not applicableNot yet recruitingVA Office of Research and Development302027-06-012026-10-05
Real-World Evaluation of Compl-AI for Predicting Early Medication Dropout in Opioid Use Disorder Treatment
Opioid Use Disorder
Not yet recruitingTools4Patient2952027-06-012026-10-01
A Feasibility and Acceptability Study of a Large Language Model-based Chatbot for Brief Alcohol Intervention Among Emerging Adults
Large language model-based chatbot brief alcohol intervention session - Alcohol Use Disorder
Not applicableNot yet recruitingMassachusetts General Hospital202027-06-012025-10-22
TMS to Improve Recovery Outcomes Among Patients With Opioid Use Disorder (OUD) and Alcohol Use Disorder (AUD)
TMS Low-Dose, TMS High-Dose - Alcohol Use Disorder, Opioid Use Disorder
Not applicableRecruitingWashington State University602027-06-012026-05-29
eTSF for Latinx Young Adults With Alcohol Use Disorder
eTSF, Educational materials - Alcohol Use Disorder (AUD)
Not applicableNot yet recruitingUniversity of Texas at Austin402027-05-012026-11-04

Showing 20 of 7454. Sign in to see all of them.

Narrower conditions

Alcoholism (1674)  ·  Opioid-Related Disorders (1473)  ·  Tobacco Use Disorder (1026)  ·  Marijuana Abuse (562)  ·  Cocaine-Related Disorders (416)  ·  Smoking Cessation (341)  ·  Behavior, Addictive (305)  ·  Smoking (288)  ·  Depression (275)  ·  Alcohol Drinking (263)  ·  Stress Disorders, Post-Traumatic (240)  ·  Anxiety Disorders (225)  ·  Chronic Pain (159)  ·  Alcohol-Related Disorders (156)

Broader conditions

Chemically-Induced Disorders (7418)  ·  Mental Disorders (7060)  ·  Behavior (2078)  ·  Alcohol-Related Disorders (1972)  ·  Narcotic-Related Disorders (1604)  ·  Pathological Conditions, Signs and Symptoms (916)  ·  Signs and Symptoms (550)  ·  Health Behavior (491)  ·  Pathologic Processes (440)  ·  Neurologic Manifestations (408)  ·  Urogenital Diseases (406)  ·  Infections (398)  ·  Communicable Diseases (358)  ·  Behavioral Symptoms (353)

Interventions

Ethanol (234)  ·  Buprenorphine (191)  ·  Therapeutics (173)  ·  Naltrexone (162)  ·  Tobacco Use Cessation Devices (137)  ·  Varenicline (123)  ·  Buprenorphine, Naloxone Drug Combination (122)  ·  nabiximols (119)  ·  Nicotine (115)  ·  Cognitive Behavioral Therapy (114)  ·  Dronabinol (101)  ·  Motivational Interviewing (101)  ·  Sugars (95)  ·  Bupropion (77)  ·  vivitrol (64)

Sponsors

Yale University (357)  ·  National Institute on Drug Abuse (NIDA) (331)  ·  Medical University of South Carolina (155)  ·  Johns Hopkins University (144)  ·  New York State Psychiatric Institute (142)  ·  VA Office of Research and Development (140)  ·  University of Pennsylvania (137)  ·  University of California, Los Angeles (106)  ·  University of California, San Francisco (92)  ·  Centre for Addiction and Mental Health (79)  ·  National Institute on Alcohol Abuse and Alcoholism (NIAAA) (79)  ·  Brown University (73)  ·  University of Washington (71)  ·  Massachusetts General Hospital (67)  ·  University of Wisconsin, Madison (67)

Countries

United States (5199)  ·  Canada (277)  ·  France (253)  ·  Germany (136)  ·  United Kingdom (119)  ·  Spain (102)  ·  China (97)  ·  Sweden (88)  ·  Denmark (75)  ·  Norway (71)  ·  Switzerland (55)  ·  Australia (49)  ·  Turkey (Türkiye) (49)  ·  Belgium (46)  ·  Netherlands (40)

Top investigators

Walter Ling, M.D. (35)  ·  Warren Bickel, Ph.D. (22)  ·  Dorothy Hatsukami, Ph.D. (19)  ·  James Zacny, Ph.D. (17)  ·  Elisabeth Kruse, PhD (16)  ·  Elliot Stein, Ph.D. (14)  ·  Mark Greenwald, PhD (13)  ·  Thomas R Kosten, M.D. (12)  ·  Lorenzo Leggio, M.D. (11)  ·  Herbert Kleber, M.D. (10)  ·  Kenneth Silverman, Ph.D. (10)  ·  Eric C. Strain, MD (9)  ·  Eugene Somoza, M.D., Ph.D. (9)  ·  Frances R Levin, M.D. (9)

Results publications

PMID 37142273, PMID 37230961, PMID 40342086, PMID 37335995, PMID 39868569, PMID 34611902, PMID 25630964, PMID 29912955, PMID 34231914, PMID 37795783, PMID 33348423, PMID 41085955, PMID 42560883, PMID 22700038, PMID 33605440, PMID 35287034, PMID 36063082, PMID 39101506, PMID 25911999, PMID 25938124, PMID 35420700, PMID 37393415, PMID 40833692, PMID 20707781, PMID 22339949, PMID 24896818, PMID 25227627, PMID 26582720, PMID 27342744, PMID 30865232, PMID 32086791, PMID 32280263, PMID 32608505, PMID 32628945, PMID 33079196, PMID 33788162, PMID 33884617, PMID 34242666, PMID 34255068, PMID 34295186, PMID 34532852, PMID 36208817, PMID 37011138, PMID 37023858, PMID 37657559, PMID 38236223, PMID 39240566, PMID 42423707, PMID 10776874, PMID 10964347

NIH funding

R01DA008391 (17), P50DA009236 (16), 2025 (14), P50DA009262 (13), P50DA009241 (12), P50DA018197 (12), 2023 (10), P50DA027840 (10), 2008 (8), 2014 (8), 2015 (8), 2009 (7), P50DA009250 (7), P50DA012756 (7), P60DA005186 (7)